Hikma Pharmaceuticals Regulatory News (HIK)

12 Dec 2006 14:08

Hikma Pharmaceuticals Plc12 December 2006 Appointment of Non-executive Director London, 12 December 2006 - Hikma Pharmaceuticals PLC (LSE: HIK) (DIFX: HIK) (the"Company") is pleased to announce today's appointment of Dr Ronald L. Goode asan independent non-executive director of the Company. Commenting on the appointment, Samih Darwazah, Hikma's Chairman and ChiefExecutive said, "Ron will be an excellent addition to the Board as he bringsexperience of multiple board appointments, corporate governance, strategicdevelopment and public company issues. His pharmaceutical and financialexperience will be of significant value as we continue to build our businessboth organically and through acquisitions and I am delighted that we haveattracted a businessman of his calibre and experience." During his career in the pharmaceutical industry, Dr. Goode has developedexpertise in operations on a global basis. He held key management positions atPfizer Pharmaceuticals (Vice President of Clinical Research and ScientificAffairs, Director of Marketing Research) and at G. D. Searle & Co. (Senior VicePresident of Commercial Development, President of Asia/Pacific World Area,President of Searle International Operations). He has an extensive record ofsuccess in business development, and has supervised clinical developmentprograms that led to the filing of over a dozen New Drug Approval applications,including Pfizer's Procardia XL(R) and Searle's Ambien(R). Dr. Goode haspreviously served as President and Chief Executive Officer of two publiccompanies, Unimed Pharmaceuticals, Inc. and eXegenics Inc., and as a Director ofseveral other companies, including Hokuriku Seiyaku KK and Vitro Diagnostics. Dr. Goode currently serves on the Board of Directors of Genitope Corporation andis on the Advisory Board of ART Recherches et Technologies Avancees Inc., aCanadian public medical devices company. He has also formed his own consultingcompany, The Goode Group, for the purpose of advising Boards of Directors, CEOs,investment funds, and private individuals. Dr. Goode is a director of MercyShips International, a private charity, and is a trustee of Thunderbird, theGarvin School of International Management. Dr. Goode holds a M.S. in microbiology from the University of Memphis and aPh.D. in microbial genetics from the University of Georgia. In addition to hisgeneral responsibilities as a non-executive director, Dr Goode will sit on boththe Audit and Remuneration committees of the Board. - ENDS -Enquiries: Hikma Pharmaceuticals PLC +44 20 7399 2670Susan Ringdal, Investor Relations Director Brunswick Group LLP +44 20 7404 5959Jon Coles / Justine McIlroy / Alex Tweed Notes to Editors About HikmaHikma Pharmaceuticals PLC is a multinational pharmaceutical group focused ondeveloping, manufacturing and marketing a broad range of both branded andnon-branded generic and in-licensed pharmaceutical products. Hikma's operationsare conducted through three businesses: Generic, Branded and InjectablePharmaceuticals. Hikma's operations are based principally in the United States,the Middle East and North Africa ("MENA") region and Europe. In 2005, the Grouphad revenue of $262 million and profit attributable to shareholders of $44million. At 31 December 2005, the Group had over 1,800 employees. For news andother information, please visit www.hikma.com. Regulatory There are no other details in respect of this appointment that are relevant tobe disclosed pursuant to the Listing Rules of the Financial Services Authorityor the Offered Securities Rules of the Dubai Financial Services Authority. DrGoode's appointment was made with the assistance of external recruitmentconsultants with specific experience in the global pharmaceutical sphere. This information is provided by RNS The company news service from the London Stock Exchange